New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
Arcutis Biotherapeutics Inc Ordinary Shares ARQT
News
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
Arcutis Biotherapeutics Gets FDA Approval for Atopic Dermatitis Supplemental NDA
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics Shares Jump After FDA OKs Skin-Condition Treatment
United States